SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding (SHIELD)

Keating et al., NCT04478019, SHIELD, NCT04478019

Jun 2022

Source PDF All Studies Meta AnalysisMeta

245 participant chlorhexidine + PVP-I prophylaxis RCT with results not reported over 1 year after completion.

4 chlorhexidine RCTs have results missing long after expected Jacox, Keating, Mira, Xie
The trials report a total of 512 patients, with 3 trials having actual enrollment of 422, and the other estimated.

Important missing comments or errors? Let us know.

This study includes chlorhexidine and povidone-iodine.

Keating et al., 30 Jun 2022, Randomized Controlled Trial, USA, this trial uses multiple treatments in the treatment arm (combined with PVP-I) - results of individual treatments may vary, trial NCT04478019 (history) (SHIELD).

Contact: ns2@medicine.wisc.edu, dshirley@medicine.wisc.edu, jakeating@medicine.wisc.edu, SHIELD@medicine.wisc.edu, klhaight@medicine.wisc.edu, jperzynski@medicine.wisc.edu, mzimbric@medicine.wisc.edu.

All Studies All Outcomes Submit Updates or Corrections

This Paper Chlorhexidine All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0